CN103271897A - Applications of mesna in preparation of anti-angiogenesis drugs - Google Patents
Applications of mesna in preparation of anti-angiogenesis drugs Download PDFInfo
- Publication number
- CN103271897A CN103271897A CN2013102201782A CN201310220178A CN103271897A CN 103271897 A CN103271897 A CN 103271897A CN 2013102201782 A CN2013102201782 A CN 2013102201782A CN 201310220178 A CN201310220178 A CN 201310220178A CN 103271897 A CN103271897 A CN 103271897A
- Authority
- CN
- China
- Prior art keywords
- mesnaum
- angiogenesis
- blood vessel
- medicine
- brachydanio rerio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to applications of mesna in preparation of anti-angiogenesis drugs. So far, no related reports about mesan anti-angiogenesis activities are reported. The invention provides the applications of the mesna in preparation of the anti-angiogenesis drugs, antineoplastic drugs and drugs for fighting wet age-related macular degeneration. In-vivo pharmacodynamic experiments through use of angiogenesis models of zebrafish are carried out to verify that the mesna can substantially inhibit zebrafish angiogenesis and growth of transplanted human cancer cells, and has a therapeutical effect on the wet age-related macular degeneration, so that the mesna can be used in preparation of the anti-angiogenesis drugs, the drugs of anti-tumor effect or for fighting the wet age-related macular degeneration.
Description
Technical field
The present invention relates to medical technical field, the specifically application of mesnaum in preparing angiogenesis inhibitor class medicine.
Background technology
Angiogenesis (angiogenesis) and the multiple major disease height correlation of the mankind, as malignant tumor, look degeneration of macula (Age-related macular degeneration old age, AMD), atherosclerosis (Atherosclerosis), rheumatic arthritis (Rheumatoid arthritis), diabetic retinopathy (Diabetic retinopathy) and neoplasm metastasis (Tumor metastasis) etc.
[1].Along with the Chinese population aging aggravates gradually, these major diseases life and health of serious harm China people at present.
1971, Judah professor Folkman of Harvard University proposed the antineoplastic vascular therapy first, and he thinks that the growth of entity tumor and diffusion depend on the formation of neovascularity in tumor, and obtains nutrient by new vessels; The formation of neovascularity and growth, promoted the transfer of tumor cell
[2 – 4].Through a large amount of fundamental research in 40 years, at present based on this therapy, the listing of existing a plurality of heavy pound patent new drug, Bevacizumab (trade name Avastin as Roche, within 2010, the global marketing volume is 6,700,000,000 dollars), the Sorafenib of Bayer (trade name Nexavar, the global marketing volume was 9.94 hundred million dollars in 2010), the Sunitinib of Pfizer (trade name Sutent, the global marketing volume was 10.7 hundred million dollars in 2010)
[5 – 6] .but these drug prices are very expensive, be the medicine giant of foreign enterprise monopolization.Domestic only have the anti-tumor angiogenesis drug of 1 real meaning to ratify listing (rhEndostatin, first sign Pharmaceutical, listing in 2005) by SFDA at present
[7], but annual sales amount seldom (2010 annual sales amounts are 2.5 hundred million RMB only
), the method that there is no participates in global competition.Secondly, due to rhEndostatin (recombinant human vascular endothelial inhibin injection, Recombinant Human Endostatin Injection) be macro-molecular protein class medicine, produce the safe preparation of this class high-purity and need very high technical threshold, and the medicine of this type half-life in vivo is shorter, thereby limited the clinical practice of these activated proteins
[7].
Looking degeneration of macula (Age-related macular degeneration is called for short AMD) old age is a kind of degeneration ophthalmic of involving macula retinae district, optical fundus.It produces the macular area degeneration because of age growth, can cause that central vision sharply descends.According to statistics, this disease is suffered from over 3,000 ten thousand people in the whole world.Degeneration of macula is divided into dryness and moist two kinds.Look degeneration of macula moist old age main because choroidal artery generates extremely, seepage appears in newborn invalid blood capillary, and the liquid of vascular leakage and then destruction macula lutea, cause central vision significantly to descend, and affects quality of life, even cecutiency.Look degeneration of macula (AMD) moist old age and become the blind arch-criminal of over-65s old people
[8-9].
The method for the treatment of moist AMD mainly contains photodynamic therapy and anti-angiogenic pharmacotherapy
[8-9].Photodynamic therapy is mainly injected photosensitive drug by vein, then adopts the non-thermal energy laser irradiation choroidal neovascularization focus of specific wavelength, and photosensitive drug is activated.Treating moist AMD by photodynamic therapy, can only stablize or reduce the risk of moist AMD visual deterioration, is not etiological treatment, can not stop the possibility of recurrence.Generally need to repeatedly treat.And want lucifuge 48 hours after treatment, and to avoid photosensitivity reaction, cause skin burn, therefore, to the patient, bring a lot of miseries.Treat at present moist AMD, the medicine gone on the market mainly contains: the Macugen (Pegaptanib of Pfizer, trade name Macugen), the ranibizumab of Novartis (Ranibizumab, trade name Lucentis), the Ai Liya (VEGF-Trap-eye of Bayer, trade name Eylea), the price of these medicines is very expensive, generally needs the administration of every menstruation intravitreal injection, and this tediously long administration process is difficult to be accepted by the patient.Therefore, to treat age-related macular degeneration be following development trend to the eye drop of development of new cheapness.
In sum, seek new angiogenesis inhibitor and effectively treat above-mentioned disease and become the research and development focus in micromolecular compound, it is extremely urgent that exploitation has the patent targeting angiogenesis inhibitor small-molecule drug of independent intellectual property right.
Mesnaum, Chinese: mesnaum; English name: Mesna; Chemical name: 2-mercaptoethyl sodium sulfonate; No. Cas: 19767-45-4; Molecular formula: C
2h
5naO
3s
2; Molecular weight: 164.2.Mesnaum has sulfydryl (SH), can be combined with the toxic metabolite acrylic aldehyde that the anti-tumor chemotherapeutic medicines such as cyclophosphamide or ifosfamide produce and form nontoxic compound, and per urethra is discharged, thereby has avoided the generation of cystitis.The adjuvant as cyclophosphamide or ifosfamide etc. for the anti-tumor chemotherapeutic medicine clinically; in the time of can preventing from carrying out chemotherapy of tumors with antitumor drug such as high dose cyclophosphamide or ifosfamides; the urinary system epithelium toxicity such as the hemorrhagic cystitis caused, as the urinary system protective agent
[10 – 12].The chemical structural formula of mesnaum is as follows:
There is not yet the active relevant report of relevant mesnaum angiogenesis inhibitor (anti-angiogenesis).
Summary of the invention
The present inventor is unexpected to be found, mesnaum has the effect of angiogenesis inhibitor.
Therefore, the invention provides the application of mesnaum in preparing angiogenesis inhibitor class medicine.
The present invention also provides the application of mesnaum in preparing antitumor drug, and described mesnaum prevents or treat tumor by the generation that suppresses neovascularity in tumor.
The present invention also provides mesnaum preparing the application of moisture resistance in looking the degeneration of macula medicine old age, and described mesnaum prevents or treats and look degeneration of macula moist old age by suppressing the choroidal artery paraplasm.
Said medicine is oral administered dosage form, injecting medicine-feeding form, mucosa delivery dosage form or percutaneous dosing dosage form, more specifically, and as tablet, capsule, granule, oral liquid, injection, patch or gel form.Can pass through the methods known in the art useful in preparing drug formulations.
The present invention utilizes the Brachydanio rerio angiogenesis model to carry out the anti-angiogenic pharmacodynamic experiment of mesnaum.With traditional blood vessel study model (mouse of Rodents and chick embryo allantois mould), compare, a large amount of studies confirm that at present, Brachydanio rerio is optimal Vascular Biology and anti-angiogenic medicaments evaluation model
[13 – 23].There are shortcoming separately in the mouse of Rodents and chick embryo allantois mould
[17 – 18].By utilizing the Brachydanio rerio angiogenesis model to carry out pharmacodynamic evaluation and the checking of medicine novel targets, existing branched cancer therapy drug enters clinical front experiment (Pre-clinical Trial) or clinical trial (Clinical Trial) stage (comprising the medicine that obtains FDA approval listing), as Vatalanib (Novartis)
[19], Compound 6 (TargeGen)
[20], Rosuvastatin
[21], Solenopsin (Eli Lilly)
[22]deng; A kind of old medicine for the treatment of malignant tumor of mainly finding based on Brachydanio rerio angiogenesis inhibitor model is newly used medicine---and reaction stops (Thalidomide) and has obtained FDA approval listing
[23].
In the Brachydanio rerio body, vascular pattern confirms, mesnaum is to blood vessel (intersegmental vessel between the Brachydanio rerio body segment, ISV) blood vessel (Subintestinal vessel and under intestinal, SIV) function of remarkable inhibition is arranged, and present certain dosage according to patience, therefore, can be used for preparing the angiogenesis inhibitor inhibitor.
As cancer transplantation model and moist looking aspect the degeneration of macula model, large quantity research is also arranged Brachydanio rerio both at home and abroad
[24-29].Through Brachydanio rerio Human colon cancer (Colo320) transplantation model, confirm, mesnaum can significantly suppress the growth of Human colon cancer (Colo320); Look the degeneration of macula model validation through Brachydanio rerio, mesnaum has significant therapeutic effect to looking degeneration of macula moist old age.Therefore, mesnaum can be used for antitumor and treats and look degeneration of macula moist old age.
Mesnaum of the present invention is safe, raw material sources are extensive, is aided with pharmaceutically acceptable adjuvant, adopts the conventional formulation technology to can be made into various oral, injections, external preparation, has good DEVELOPMENT PROSPECT.
The accompanying drawing explanation
fig. 1for blood vessel (ISV) model between after fertilization 48h of the present invention (48hpf) blood vessel transgenic fluorescence Brachydanio rerio body segment.Confine the position of zone for the local amplifying observation of Brachydanio rerio body segment blood vessel network.Arrow indication body intersegmental blood vessel (ISV, intersegmental vessel).
fig. 2for the inhibition of qualitative observation mesnaum of the present invention to angiogenesis (angiogenesis) between the Brachydanio rerio body segment.Figure a-c, the Brachydanio rerio of after fertilization 23hpf, through drug treating 25h, is 48hpf during observation mutually.The figure negative contrast of a (0.1%DMSO), figure b is the mesnaum processed group, the figure positive contrast of c (10 μ M lovastatin).With negative control, compare, 10 μ M mesnaum can suppress the generation of blood vessel between the Brachydanio rerio body segment (ISV).
fig. 3for blood vessel (SIV) model under 72 hours (72hpf) blood vessel transgenic fluorescence Brachydanio rerio intestinal of after fertilization of the present invention.Confine the position of zone for the local amplifying observation of blood vessel (SIV) network under intestinal.Blood vessel (SIV, subintestinal vessel) under arrow indication intestinal.
fig. 4for the inhibition of qualitative observation mesnaum of the present invention to blood vessel (SIV) under the Brachydanio rerio intestinal.Figure a-c, the Brachydanio rerio of after fertilization 48hpf, through drug treating 24h, is 72hpf during observation mutually.The figure negative contrast of a (0.1%DMSO), figure b is the mesnaum processed group, the figure positive contrast of c (10 μ M lovastatin).Dashed region is blood vessel under intestinal.With negative control, compare, 10 μ M mesnaum significantly suppress the generation of blood vessel under the Brachydanio rerio intestinal (SIV).
fig. 5for suppression ratio and the IC of mesnaum of the present invention to blood vessel (SIV) generation under the Brachydanio rerio intestinal
50.The suppression ratio that mesnaum generates blood vessel (SIV) under the Brachydanio rerio intestinal presents step increase along with the rising of concentration, the suppression ratio that each concentration mesnaum group generates blood vessel (SIV) under the Brachydanio rerio intestinal is respectively: 0.25 μ M(6.9%), 0.5 μ M(18%), 1 μ M(39%), 2.5 μ M(48%), 10 μ M(69%), 26.95 μ M(85%).
fig. 6antitumor drug effect for Brachydanio rerio Human colon cancer of the present invention (Colo320) transplantation model evaluation mesnaum.Figure a-f, transplant the Brachydanio rerio of the rear 2dpf of Human colon cancer (Colo320) through drug treating 4d, during observation, is 6dpf mutually.Figure a is blank, the figure negative contrast of b (0.1%DMSO), the mesnaum processed group that figure d-f is variable concentrations, the figure positive contrast of c (1000 μ M5-FU).
fig. 7for the growth inhibition ratio of mesnaum of the present invention to the carcinoma transplanted cell.Mesnaum presents step increase to the suppression ratio of mankind's carcinoma transplanted Growth of Cells along with the rising of concentration, three concentration mesnaum group suppression ratio are respectively: 1 μ M(10.3%), 2.5 μ M(21.2%), 10 μ M(38.9%).
fig. 8for quantitative assessment mesnaum of the present invention to looking the therapeutical effect of degeneration of macula.Figure a-e, the Brachydanio rerio of after fertilization 1dpf, through drug treating 4d, is 5dpf during observation mutually.In border circular areas shown in dotted line, it is choroidal artery.The figure negative contrast of a (0.1%DMSO), figure b is model group (1mg/ml cobaltous chloride), the mesnaum processed group that figure c-e is various dose.
fig. 9for mesnaum of the present invention to the paraplasm suppression ratio of choroidal artery.Mesnaum presents step increase to the paraplasm suppression ratio of choroidal artery along with the rising of injected dose, three mesnaum dosage group suppression ratio are respectively: 0.16 μ g(10.5%), 0.55 μ g(25.7%), 1.64 μ g(34.3%).
The specific embodiment
Below in conjunction with Figure of description and embodiment, the present invention is further elaborated, but protection scope of the present invention is not limited to this.
The Brachydanio rerio initialism of being correlated with
After fertilization hourage: hpf-hours postfertilization
Back of the body major axis blood vessel: DLAV-dorsal longitudinal anastomotic vessel
Blood vessel between body segment: ISV-intersegmental vessel
Dorsal aorta: DA-dorsal aorta
Posterior cardinal vein: PCV-posterior cardinal vessel
Subintestinal vein blood vessel: SIV-subintestinal vessel
Green fluorescent protein: GFP-green fluorescent protein
embodiment 1the inhibition of qualitative observation mesnaum to blood vessel (ISV) generation model between the Brachydanio rerio body segment
Brachydanio rerio:
The Brachydanio rerio that the present embodiment is used is blood vessel transgenic green fluorescence Brachydanio rerio (a kind of gene of being expressed by the Brachydanio rerio endothelial-cell specific drives green fluorescent protein at Brachydanio rerio vascular endothelial cell specifically expressing as driven element), and raising and Application standard strictly carry out with reference to U.S.'s management of laboratory animal and the requirement of using committee (IACUC).
The water (Fish water) of breeding fish:
Compound method: 1L reverse osmosis water (reverse osmosis (RO) water) adds 0.3g sea salt (Instant Ocean salts).
Dimethyl sulfoxide (DMSO, analytical pure):
Buy in Shanghai Jing Chun Industrial Co., Ltd. (article No. #1095515, lot number #30573).0.1% DMSO solution (negative control) preparation: during use, with the water of breeding fish, be mixed with the working solution that concentration is 0.1%, now with the current.
Lovastatin (positive control):
Buy the U.S. logical sequence in Dalian, purity is greater than 98% (HPLC method).During use, with 0.1% DMSO solution preparation, become the required concentration of experiment, in this experiment, the working concentration of positive control drug is 10 μ M.
Mesnaum is bought the company in Sigma-Aldrich, becomes the mesnaum solution of variable concentrations during use with 0.1% DMSO solution preparation, and working concentration is 10 μ M.
The Brachydanio rerio vascular endothelial cell sprouts from after fertilization 20hpf, and the 30-31hpf left and right forms blood vessel network between main body segment, and as blood vessel (ISV) between back of the body major axis blood vessel (DLAV) and body segment, 48hpf forms complete axon blood vessel network basically
[30], blood vessel (ISV) between high-visible complete body segment now.Between complete body segment, blood vessel mainly refers to connect that section blood vessel between (DLAV) between dorsal aorta (DA) and back of the body major axis blood vessel, sees
fig. 1(vascular pattern between 48hpf blood vessel transgenic fluorescence Brachydanio rerio body segment).Experimental technique is as follows:
(1) experiment grouping and embryo process: get 45 well-developed zebrafish embryos, during fetal development, be after fertilization 23hpf (hour-postfertilization mutually, hpf), be divided at random 3 groups of (negative control group, the mesnaum processed group, positive controls), every group of embryo's quantity is 15.During operation by embryo's uniform distribution to 48 porocyte culture plate (Greiner, Germany), 15, every hole embryo, every hole embryo raises water 1ml.
(2) drug treating: the medicinal liquid that will prepare in advance rapidly with pipettor (range 100～1000 μ l, Eppendorf) adds Zhong，Mei hole, the hole 1ml that 48 porocyte culture plates are corresponding.Before adding medicinal liquid, with pipettor (range 10～1000 μ l, Eppendorf), the raising water of hatching the embryo in 48 orifice plates is shifted out as possible, this operation needs to complete in advance at short notice, to prevent embryo's drying.The experimental situation temperature is controlled at 28.5 ℃ of left and right, relative humidity 40～70%.Then with masking foil, 48 orifice plates are wrapped, carry out the experiment labelling, be positioned over rapidly in the Brachydanio rerio incubator and continue to cultivate 24h (the incubator temperature is controlled at 28.5 ± 0.5 ℃).
(3) Phenotypic Observation and statistics: observe each hole embryo's phenotype under Stereo microscope, observation index: observe the impact of medicine on aspects such as fetal development, blood circulation and heartbeats.Then, the affected embryo of blood circulation being placed under body formula fluorescence microscope (Nikon AZ100 body formula fluorescence microscope) and further observing and take pictures, is 48hpf mutually while taking pictures, and to confirm angiogenesis, suppresses phenotype.
Experimental result is shown in
fig. 2: with negative control, compare, 25 μ M mesnaum can suppress the generation of blood vessel between the Brachydanio rerio body segment (ISV), show as part intersegmental blood vessel disappearance.
embodiment 2the inhibition of qualitative observation mesnaum to blood vessel (SIV) generation model under the Brachydanio rerio intestinal
Blood vessel under the Brachydanio rerio intestinal (SIV, subintestinal vessel) is grown in the yolk sac both sides, and its shape is like one basket, and blood vessel under intestinal (SIV) is about 50～100 μ m by the body segment veutro to the length of downward-extension
[15-16].See
fig. 3(vascular pattern under 72hpf blood vessel transgenic fluorescence Brachydanio rerio intestinal).Experimental technique is as follows:
(1) experiment grouping and embryo process: get 45 well-developed zebrafish embryos, during fetal development, be after fertilization 48hpf (hour-postfertilization mutually, hpf), be divided at random 3 groups of (negative control group, the mesnaum processed group, positive controls), every group of embryo's quantity is 15.During operation by embryo's uniform distribution to 48 porocyte culture plate (Greiner, Germany), 15, every hole embryo, every hole embryo raises water 1ml.
(2) drug treating: see the experimental technique operating procedure (2) in embodiment 1.
(3) Phenotypic Observation and statistics: observe each hole embryo's phenotype under Stereo microscope, observation index: observe medicine to fetal development, blood circulation, the impact of the aspects such as heartbeat.Then, the affected embryo of blood circulation being placed under body formula fluorescence microscope (Nikon AZ100 body formula fluorescence microscope) and further observing and take pictures, is 72hpf mutually while taking pictures, and to confirm angiogenesis, suppresses phenotype.
Experimental result is shown in
fig. 4: with negative control, compare, 25 μ M mesnaum significantly suppress the generation of blood vessel under the Brachydanio rerio intestinal (SIV), show as blood vessel area under intestinal and reduce.
embodiment 3the inhibition of quantitative assessment mesnaum to blood vessel (SIV) generation model under the Brachydanio rerio intestinal
experimental technique:
(1) experiment grouping and embryo process: getting 240 well-developed zebrafish embryos, is after fertilization 48hpf (hour-postfertilization, hpf) mutually during fetal development, is divided at random 8 groups, sees the following form:
30 of every group of zebrafish embryo quantity.During operation by embryo's uniform distribution to 48 porocyte culture plate (Greiner, Germany), 15, every hole embryo, each drug level is processed 30 embryos, every hole embryo raises water 1ml.
(2) drug treating: see the experimental technique operating procedure (2) in embodiment 1.
(3) Phenotypic Observation and quantitative statistics: the embryo after each drug level is processed observes and takes pictures under body formula fluorescence microscope (Nikon AZ100 body formula fluorescence microscope), while taking pictures, be 72hpf mutually, impact blood vessel (SIV) under the Brachydanio rerio intestinal generated to analyze each drug level.Get at random 10 embryos from each experimental group and carry out quantitative statistics, statistical indicator is as follows:
1. blood vessel area (SIV area) under intestinal: utilize Nikon AZ100 body formula fluorescence microscope configuration
NIS-Elements 3.1 softwares are calculated
Utilize GraphPad Prism software to add up mapping, and calculate mesnaum and suppress the IC that under the Brachydanio rerio intestinal, blood vessel (SIV) generates
50, experimental result is shown in
fig. 5: the suppression ratio that mesnaum generates blood vessel (SIV) under the Brachydanio rerio intestinal presents step increase along with the rising of concentration, the suppression ratio that each concentration mesnaum group generates blood vessel (SIV) under the Brachydanio rerio intestinal is respectively: 0.25 μ M(6.9%), 0.5 μ M(18%), 1 μ M(39%), 2.5 μ M(48%), 10 μ M(69%), 25 μ M(85%).
embodiment 4brachydanio rerio Human colon cancer (Colo320) transplantation model is estimated the antitumor drug effect of mesnaum
The growth of entity tumor and diffusion depend on the formation of neovascularity in tumor, and obtain nutrient by new vessels; The formation of neovascularity and growth, promoted the transfer of tumor cell.The present embodiment is for illustrating that mesnaum can suppress growth and the migration of tumor.Experimental technique is as follows:
(1) experiment grouping and embryo process: getting the zebrafish embryo that 150 transplanting have Human colon cancer (Colo320) cell, is after fertilization 2dpf (day-postfertilization, dpf) mutually during fetal development, is divided at random 5 groups, sees the following form:
30 of every group of zebrafish embryo quantity.During operation by embryo's uniform distribution to 6 porocyte culture plate (Greiner, Germany), 30, every hole embryo, each drug level is processed 30 embryos, every hole embryo raises water 3ml.
(2) drug treating: with pipettor, rapidly pre-configured medicinal liquid is added to Zhong，Mei hole, the hole 3ml that 6 porocyte culture plates are corresponding.Then with masking foil, 6 orifice plates are wrapped, carry out the experiment labelling, be positioned in the Brachydanio rerio incubator and continue to cultivate 4d (the incubator temperature is controlled at 35.5 ± 0.5 ℃).
(3) Phenotypic Observation and quantitative statistics: the embryo after each concentration drug treating is observed and takes pictures under body formula fluorescence microscope (Nikon AZ100 body formula fluorescence microscope), while taking pictures, be 6dpf mutually, to analyze the inhibitory action of each drug level to Brachydanio rerio Human colon cancer (Colo320) transplantation model.Get at random 10 embryos from each experimental group and carry out quantitative statistics, statistical indicator is as follows:
1. the inhibitory action of qualitative evaluation mesnaum to neoplasm metastasis;
2. the inhibitory action of quantitative assessment mesnaum to tumor growth: utilize Nikon NIS-Elements 3.1 computed in software tumor cell fluorescence intensities (S), the statistical procedures result means with mean ± SE; Mesnaum is as follows to the inhibition computing formula of tumor growth:
Utilize GraphPad Prism software to add up mapping, experimental result is shown in
fig. 6～Fig. 7: mesnaum presents step increase to the suppression ratio of mankind's carcinoma transplanted Growth of Cells along with the rising of concentration, three concentration mesnaum group suppression ratio are respectively: 1 μ M(10.3%), 2.5 μ M(21.2%), 10 μ M(38.9%).
embodiment 5the quantitative assessment mesnaum is looked the therapeutical effect of degeneration of macula to moist old age
Look degeneration of macula moist old age main because choroidal artery generates extremely, seepage appears in newborn invalid blood capillary, the liquid of vascular leakage and then destruction macula lutea.Cobaltous chloride can be induced Brachydanio rerio retina choroid plexus blood vessel hyperplasia, visual cell degeneration, is similar to the change that the mankind look degeneration of macula moist old age
[31].The present embodiment is for illustrating that mesnaum has therapeutic effect to looking degeneration of macula moist old age.Experimental technique is as follows:
(1) experiment grouping and embryo process: getting 150 well-developed zebrafish embryos, is after fertilization 1dpf (day-postfertilization, dpf) mutually during fetal development, is divided at random 5 groups, sees the following form:
30 of every group of zebrafish embryo quantity.During operation by embryo's uniform distribution to 6 porocyte culture plate (Greiner, Germany), 30, every hole embryo, every hole embryo raises water 3ml.
(2) drug treating: add DMSO in negative control group, making its final concentration is 0.1%; Add cobaltous chloride in model group, making its final concentration is 1 mg/ml; Mesnaum, by the administration of microinjection mode, is all injected 30 embryos for every group, after injection, the embryo is put into respectively to the raising water that 3ml contains 1 mg/ml cobaltous chloride by group.
(3) Phenotypic Observation and quantitative statistics: the embryo after each dose drug is processed observes and takes pictures under body formula fluorescence microscope (Nikon AZ100 body formula fluorescence microscope), while taking pictures, be 5dpf mutually, to analyze the inhibitory action of each drug dose to Brachydanio rerio eye choroidal abnormalities hypertrophy blood vessel.Get at random 10 embryos from each experimental group and carry out quantitative statistics, statistical indicator is as follows:
1. the inhibitory action of qualitative evaluation mesnaum to eye choroidal abnormalities hypertrophy blood vessel;
2. the inhibitory action of quantitative assessment mesnaum to choroidal abnormalities hypertrophy blood vessel: utilize NIS-Elements 3.1 computed in software choroidal abnormalities hypertrophy blood vessel fluorescence intensities (S), the statistical procedures result means with mean ± SE; Mesnaum is as follows to the inhibition computing formula of choroidal abnormalities hypertrophy blood vessel:
Utilize GraphPad Prism software to add up mapping, experimental result is shown in
fig. 8～Fig. 9: mesnaum presents step increase to the paraplasm suppression ratio of choroidal artery along with the rising of dosage, three mesnaum dosage group suppression ratio are respectively: 0.16 μ g(10.5%), 0.55 μ g(25.7%), 1.64 μ g(34.3%).
list of references:
[1] Folkman J. Angiogenesis: an organizing principle for drug discovery
Nat Rev Drug Discov. 2007 Apr;6(4):273-86.
[2] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 1996 Aug 9;86(3):353-64.
[3] Li CY, Shan S, Cao Y, et al. Role of incipient angiogenesis in cancer metastasis.
Cancer Metastasis Rev. 2000;19(1-2):7-11.
[4] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.
Nature. 2000
Sep 14;407(6801):249-57.
[5] Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy.
CA Cancer J Clin. 2009 Mar-Apr;59(2):111-37.
[6] Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects.
CA Cancer J Clin. 2010 Jul-Aug;60(4):222-43.
[7] Guan great Gang. Research of Recombinant Human Endostatin combined chemotherapy Clinical advances [J]. modern tumor medical science, 2011,19(2): 400-403.
[8] Fang Yuxin, often quiet. the anti-vascular endothelial growth factor of newly wishing of patients with age-related macular degeneration is treated [J]. Chinese medical information Leader, 2007,22(24): 16-17.
[9] Li Hairong, Li Jianhua .Anti-VEGF treats clinical assessment and the application of moist age-related macular degeneration. the Chinese Medicine guide, and 2010,8(25): 32-35.
[10] Li X, Yang S, Lv X, , et al. The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats.
J Gynecol Oncol. 2013 Apr;24(2):177-85.
[11] Song J, Liu L, Li L, et al. Protective effects of lipoic acid and mesna on cyclophosphamide-induced haemorrhagic cystitis in mice.
Cell Biochem Funct. 2013 May 5.
[12] Zhang Y, Kawedia JD, Myers AL, et al. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. J
Oncol Pharm Pract. 2013 Mar 19.
[13] Lyons ET, Tolliver SC, Kuzmina TA, et al. Further evaluation in field tests of the activity of three anthelmintics (fenbendazole, oxibendazole, and pyrantel pamoate) against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010).
ParasitolRes, 2011,109(4): 1193-1197.
[14] Wang C, Tao W, Wang Y,et al. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.
Eur Urol, 2010, 58(3):418-26.
[15] Cheng J, Gu YJ, Wang Y, et al. Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos.
Int J Nanomedicine. 2011;6:2007-21.
[16] Serbedzija GN, Flynn E, Willett CE. Zebrafish angiogenesis: a new model for drug screening.
Angiogenesis. 1999;3(4):353-9.
[17] Hasan J, Shnyder SD, Bibby M, et al. Quantitative angiogenesis assays in vivo--a review.
Angiogenesis. 2004; 7: 1-16.
[18] Nicoli S, Presta M. The zebrafish/tumor xenograft angiogenesis assay.
Nat Protoc. 2007;2(11):2918-23.
[19] Chan J, Bayliss PE, Wood JM,et al. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach.
Cancer Cell. 2002 Apr;1(3):257- 67.
[20] Murphy EA, Shields DJ, Stoletov K, et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/ B-RAF.
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304.
[21] Wang C, Tao W, Wang Y, et al. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.
Eur Urol. 2010 Sep;58(3):418-26.
[22] Arbiser JL, Kau T, Konar M, et al. Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
Blood. 2007 Jan 15; 109(2):560-5.
[23] Yabu T, Tomimoto H, Taguchi Y, et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate.
Blood. 2005 Jul 1;106(1):125-34.
[24] Herpers R, van de Kamp E, Duckers HJ, et al. Redundant Roles for Sox7 and Sox18 in Arteriovenous Specification in Zebrafish.
Circ Res. 2008 Jan 4;102(1):12-5.
[25] Marques IJ, Weiss FU, Vlecken DH, et al. Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model.
BMC Cancer. 2009
Apr 28; 9(1):128.
[26] Konantz M, Balci TB, Hartwig UF, et al. Zebrafish xenografts as a tool for in vivo studies on human cancer[J].
Ann. N.Y. Acad. Sci. 2012, (1266): 124-137.
[27] Chu DLH, Li VWT, Yu RMK. Leptin: Clue to poor appetite in oxygen-starved fish[J].
Molecular and Cellular Endocrinology, 2010, (319): 143-146.
[28] Rooijen E, Voest EE, Logister I, et al. Von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathied in zebrafish[J].
Disease Models & Mechanisms, 2010, (3): 343-353.
[29] Bibliowicz J, Tittle RK, Gross JM. Towards a better understanding of human eye disease: insights from the zebrafish, Danio rerio[J].
Prog Mol Biol Transl Sci, 2011, (100): 287-330.
[30] Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries[J].
Nature. 2007 Feb 15;445(7129):781-4.
[31] Yu RM, Chu DL, Tan TF, et al. Leptin-mediated modulation of steroidogenic gene expression in hypoxic zebrafish embryos: implications for the disruption of sex steroids[J].
Environ Sci Technol, 2012, 46(16): 9112-9119。
Claims (9)
1. the application of mesnaum in preparing angiogenesis inhibitor class medicine.
2. application according to claim 1, is characterized in that, described medicine is oral administered dosage form, injecting medicine-feeding form, mucosa delivery dosage form or percutaneous dosing dosage form.
3. application according to claim 1, is characterized in that, described medicine is tablet, capsule, granule, oral liquid, injection, patch or gel form.
4. the application of mesnaum in preparing antitumor drug.
5. application according to claim 4, is characterized in that, described mesnaum prevents or treat tumor by the generation that suppresses neovascularity in tumor.
6. application according to claim 4, is characterized in that, described medicine is tablet, capsule, granule, oral liquid, injection, patch or gel form.
7. mesnaum is preparing the application of moisture resistance in looking the degeneration of macula medicine old age.
8. application according to claim 7, is characterized in that, described mesnaum prevents or treats and look degeneration of macula moist old age by suppressing the choroidal artery paraplasm.
9. application according to claim 7, is characterized in that, described medicine is tablet, capsule, granule, oral liquid, injection, patch or gel form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102201782A CN103271897A (en) | 2013-06-04 | 2013-06-04 | Applications of mesna in preparation of anti-angiogenesis drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102201782A CN103271897A (en) | 2013-06-04 | 2013-06-04 | Applications of mesna in preparation of anti-angiogenesis drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103271897A true CN103271897A (en) | 2013-09-04 |
Family
ID=49054124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102201782A Pending CN103271897A (en) | 2013-06-04 | 2013-06-04 | Applications of mesna in preparation of anti-angiogenesis drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103271897A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007059111A2 (en) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| CN101442998A (en) * | 2006-03-16 | 2009-05-27 | 比奥纽默里克药物公司 | Anti-cancer activity augmentation compounds and formulationsand methods of use thereof |
| WO2012125510A1 (en) * | 2011-03-11 | 2012-09-20 | Gilead Calistoga Llc | Combination therapies for hematologic malignancies |
| CN103037913A (en) * | 2010-06-09 | 2013-04-10 | 森普鲁斯生物科学公司 | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions |
-
2013
- 2013-06-04 CN CN2013102201782A patent/CN103271897A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007059111A2 (en) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| CN101442998A (en) * | 2006-03-16 | 2009-05-27 | 比奥纽默里克药物公司 | Anti-cancer activity augmentation compounds and formulationsand methods of use thereof |
| CN103037913A (en) * | 2010-06-09 | 2013-04-10 | 森普鲁斯生物科学公司 | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions |
| WO2012125510A1 (en) * | 2011-03-11 | 2012-09-20 | Gilead Calistoga Llc | Combination therapies for hematologic malignancies |
Non-Patent Citations (2)
| Title |
|---|
| 刘学文等: "环氧化酶-2在白血病患者骨髓细胞中表达及与血管新生的关系", 《中国实验血液学杂志》 * |
| 李明等: "抗血管新生治疗白血病的研究", 《中华内科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11407811B2 (en) | Fusion protein, preparation method therefor and use thereof | |
| Lis et al. | Circadian timing in cancer treatment: the biological foundation for an integrative approach | |
| CN103479662A (en) | Application of auranofin to preparation of anti-angiogenic medicine | |
| CN105418769B (en) | Fusion protein with functions of resisting tumor and inflammation and treating ophthalmic diseases and preparation method and application thereof | |
| Kaczmarek et al. | Intravitreal HDAC inhibitor belinostat effectively eradicates vitreous seeds without retinal toxicity in vivo in a rabbit retinoblastoma model | |
| US11542311B2 (en) | Fusion protein, preparation method therefor and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament | |
| CN103054866A (en) | Application of chloroxine in preparing anti-angiogenesis medicine | |
| CN103142601A (en) | Application of PCI (Percutaneous Coronary Intervention)-32765 for preparing anti-angiogenic medicines | |
| CN103040823A (en) | Application of vinpocetine in preparation of anti-angiogenic medicament | |
| US20190351011A1 (en) | Pharmaceutical composition for anti-angiogenesis containing cyclic pentadepsipeptide as an effective ingredient | |
| CN103054846B (en) | Anti-angiogenic compound and usage thereof | |
| CN103054858A (en) | Application of oxibendazole in preparing anti-angiogenesis medicine | |
| CN103271897A (en) | Applications of mesna in preparation of anti-angiogenesis drugs | |
| CN103251588A (en) | Application of phenytoin sodium in preparing anti-angiogenesis medicine | |
| CN103110614B (en) | Application of suloctidil to prepare anti-angiogenesis medicine | |
| CN107375258A (en) | A kind of antineoplastic combination medicine and its purposes in cancer therapy drug is prepared | |
| CN103251633A (en) | Application of phenazopyridine in preparing anti-angiogenesis medicine | |
| CN103040800A (en) | Application of gemfibrozil in preparation of anti-angiogenic medicaments | |
| CN103054840B (en) | Application of levalbuterol to preparation of anti-angiogenesis drugs | |
| CN115154604A (en) | Self-delivery nano system based on inflammatory management strategy, preparation method and application | |
| CN107698609A (en) | Method and application based on human serum albumins IB subdomain synthesizing antitumor metal prodrugs | |
| CN106727603A (en) | Application of the DEMETHYLZEYLASTERAL in the medicine for preparing treatment cancer of pancreas | |
| CN105560302A (en) | Application of Geranium wilfordii Maxim. aqueous extract in preparation of anti-angiogenesis drugs | |
| US20120064178A1 (en) | Cell-8 Solution | |
| CN101653607B (en) | Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HANGZHOU LEISUO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LI CHUNQI Effective date: 20150520 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150520 Address after: Hangzhou City, Zhejiang province Xiaoshan District 311202 North Street Jincheng Road No. 1038, room 817 Applicant after: Hangzhou Leisuo Pharmaceutical Co., Ltd. Address before: Hangzhou City, Zhejiang province 311231 - Xiaoshan economic and Technological Development Zone Land biological loop Applicant before: Li Chunqi |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130904 |